Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 1
1984 1
1985 5
1986 10
1987 5
1988 2
1989 11
1990 1
1991 4
1992 8
1993 2
1994 8
1995 7
1996 2
1997 5
1998 7
1999 8
2000 11
2001 9
2002 10
2003 6
2004 9
2005 16
2006 19
2007 20
2008 31
2009 20
2010 23
2011 20
2012 21
2013 27
2014 21
2015 23
2016 23
2017 22
2018 15
2019 10
2020 10
2021 11
2022 4
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

425 results

Results by year

Filters applied: . Clear all
Page 1
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: van gaal lf. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: van gaal lf. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. Diabetes Obes Metab. 2022. PMID: 35441470 Free PMC article. Clinical Trial.
Progress and challenges in anti-obesity pharmacotherapy.
Bessesen DH, Van Gaal LF. Bessesen DH, et al. Among authors: van gaal lf. Lancet Diabetes Endocrinol. 2018 Mar;6(3):237-248. doi: 10.1016/S2213-8587(17)30236-X. Epub 2017 Sep 14. Lancet Diabetes Endocrinol. 2018. PMID: 28919062 Review.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Among authors: van gaal l. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Clinical Trial.
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human.
Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, Kimura I, Leloire A, Liu N, Iida K, Choquet H, Besnard P, Lecoeur C, Vivequin S, Ayukawa K, Takeuchi M, Ozawa K, Tauber M, Maffeis C, Morandi A, Buzzetti R, Elliott P, Pouta A, Jarvelin MR, Körner A, Kiess W, Pigeyre M, Caiazzo R, Van Hul W, Van Gaal L, Horber F, Balkau B, Lévy-Marchal C, Rouskas K, Kouvatsi A, Hebebrand J, Hinney A, Scherag A, Pattou F, Meyre D, Koshimizu TA, Wolowczuk I, Tsujimoto G, Froguel P. Ichimura A, et al. Among authors: van gaal l. Nature. 2012 Feb 19;483(7389):350-4. doi: 10.1038/nature10798. Nature. 2012. PMID: 22343897 Free article.
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Astrup A, et al. Among authors: van gaal l. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Int J Obes (Lond). 2012. PMID: 21844879 Free PMC article. Clinical Trial.
Cardio-renal-metabolic disease in primary care setting.
Ibrahim M, Ba-Essa EM, Baker J, Cahn A, Ceriello A, Cosentino F, Davies MJ, Eckel RH, Van Gaal L, Gaede P, Handelsman Y, Klein S, Leslie RD, Pozzilli P, Del Prato S, Prattichizzo F, Schnell O, Seferovic PM, Standl E, Thomas A, Tuomilehto J, Valensi P, Umpierrez GE. Ibrahim M, et al. Among authors: van gaal l. Diabetes Metab Res Rev. 2024 Mar;40(3):e3755. doi: 10.1002/dmrr.3755. Epub 2023 Dec 19. Diabetes Metab Res Rev. 2024. PMID: 38115715 Review.
NAFLD in type 1 diabetes: overrated or underappreciated?
Mertens J, Van Gaal LF, Francque SM, De Block C. Mertens J, et al. Among authors: van gaal lf. Ther Adv Endocrinol Metab. 2021 Nov 23;12:20420188211055557. doi: 10.1177/20420188211055557. eCollection 2021. Ther Adv Endocrinol Metab. 2021. PMID: 34840719 Free PMC article. Review.
Therapeutic approaches for non-alcoholic steatohepatitis.
Van Gaal LF, Mertens J, Francque S, De Block C. Van Gaal LF, et al. Ther Adv Endocrinol Metab. 2021 Sep 3;12:20420188211034300. doi: 10.1177/20420188211034300. eCollection 2021. Ther Adv Endocrinol Metab. 2021. PMID: 34497708 Free PMC article.
425 results